CMS has used similar tools in the past to test premium stabilization, drug vouchers, and reduced cost sharing for generics without changing statutory coverage rules
Who Should Consider NAD + Injections
Important Safety Information for RYBELSUS WARNING: RISK OF THYROID C-CELL TUMORS In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures
Who Will Be Able to Take Retatrutide
Key distinctions in the evidence: Tesamorelin: licensed in the US, narrowly indicated, established in HIV-related lipodystrophy, with effects that reverse on stopping treatment Retatrutide: investigational, broader metabolic potential, not yet approved anywhere globally Patients and clinicians should interpret early-phase data for retatrutide with appropriate caution
Studies have found that Bacteroides can hinder C